Form 4: MindMed Chief Medical Officer Sells Shares for Tax Obligations Under Pre-Arranged Plan
Insider Transaction Report
Mind Medicine (MindMed) Inc.'s Chief Medical Officer, Daniel Karlin, sold 7,848 common shares at a weighted average price of $6.80 to satisfy tax withholding obligations related to vested restricted stock units.
Summary
- Daniel Karlin, Chief Medical Officer of Mind Medicine (MindMed) Inc. (MNMD), reported a transaction on June 25, 2025.
- He sold 7,848 common shares of the company.
- The shares were sold at a weighted average price of $6.80, with individual transaction prices ranging from $6.67 to $7.03.
- The purpose of the sale was to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units.
- This transaction was executed pursuant to a sell-to-cover election under a Rule 10b5-1 plan, which was adopted on June 14, 2022.
- Following this transaction, Daniel Karlin directly beneficially owns 438,329 common shares.
Sentiment
Score: 7
Explanation: The transaction is a routine 'sell-to-cover' for tax purposes under a pre-arranged plan, which is generally viewed neutrally to slightly positive as it's not a discretionary sale indicating a lack of confidence. The number of shares sold is also relatively small compared to the total holdings.
Positives
- The sale was a 'sell-to-cover' transaction, specifically for tax withholding obligations, which is a common and often necessary action for executives receiving equity compensation.
- The transaction was executed under a pre-arranged Rule 10b5-1 plan, adopted on June 14, 2022, indicating it was not a discretionary sale based on new, non-public information.
Negatives
- An insider sale, even for tax purposes, can sometimes be misinterpreted by the market as a lack of confidence, although this specific type of sale is generally less concerning.
Future Outlook
No forward-looking statements or guidance are provided in this Form 4 filing.
Industry Context
This is a routine insider transaction filing and does not provide broader industry context or trends.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Policy Adherence | The transaction was executed under a Rule 10b5-1 plan adopted on June 14, 2022, which is a common corporate governance practice allowing insiders to pre-arrange trades to avoid accusations of trading on material non-public information. | 06/14/2022 | Enhances transparency and reduces potential for insider trading allegations by pre-scheduling trades. |
Related Party Transactions
- Daniel Karlin, Chief Medical Officer, sold shares of Mind Medicine (MindMed) Inc., which is a transaction between an insider and the company's equity, albeit through the open market.
Stakeholder Impact
- Shareholders: Minimal direct impact as the sale is a routine tax-related transaction and not indicative of a change in management's confidence in the company's prospects. The number of shares sold is small relative to total outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 06/14/2022 | Date the Rule 10b5-1 plan was adopted. |
| 06/25/2025 | Date of the reported transaction (sale of common shares). |
| 06/26/2025 | Date the Form 4 was signed by the attorney-in-fact for Daniel Karlin. |
Keywords
Mind Medicine, MindMed, MNMD, SEC Form 4, Insider Trading, Stock Sale, Restricted Stock Units, RSU, Tax Withholding, Rule 10b5-1, Daniel Karlin, Chief Medical Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.